Bolt Biotherapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
14/08/2024 12:02
* Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected
to show
a fall in quarterly revenue when it reports results on November
7 (estimated) for the period ending September 30 2024
* The Redwood City California-based company is expected to
report
a 43.7% decrease in revenue to $1.423 million from $2.53 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Bolt Biotherapeutics Inc
is
for a loss of 30 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $1.25, above its last closing price
of $0.70.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.52 -0.48 -0.46 Beat 4.2
Mar. 31 2024 -0.50 -0.51 -0.28 Beat 45.1
Dec. 31 2023 -0.44 -0.48 -0.47 Beat 2.4
Sep. 30 2023 -0.50 -0.50 -0.43 Beat 14
Jun. -0.50 -0.49 -0.48 Beat 1.4
30 2023
Mar. 31 2023 -0.51 -0.51 -0.45 Beat 12.1
Dec. 31 2022 -0.60 -0.53 Beat 11.4
Sep. 30 2022 -0.56 -0.56 -0.58 Missed -3
This summary was machine generated August 14 at 11:01 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)